يعرض 1 - 10 نتائج من 12 نتيجة بحث عن '"Gros Subías, Luis"', وقت الاستعلام: 0.96s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المصدر: Moreno, Lucas; Teira, Pierre; Croop, James M; Gerber, Nicolas U; André, Nicolas; Aerts, Isabelle; Gros Subias, Luis; De Wilde, Bram; Bautista, Francisco; Turpin, Brian; Kunduri, Srinivasa; Hamidi, Ali; Lawrence, Tatiana; Streby, Keri A (2023). A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. Frontiers in Pediatrics, 11:1183295.

    مصطلحات موضوعية: Medical Clinic, 610 Medicine & health

    وصف الملف: application/pdf

    العلاقة: https://www.zora.uzh.ch/id/eprint/252517/1/ZORA252517.pdfTest; info:pmid/37292376; urn:issn:2296-2360

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Janeway KA Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA. Gros L Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d'Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Schwartz S Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany. Daugherty C, Hill C BTG International Inc., Conshohocken, Pennsylvania, USA. Gallardo E Protherics Medicines Development Ltd., London, UK, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Pediatric Blood & Cancer;70(9); https://doi.org/10.1002/pbc.30506Test; Janeway KA, Gros L, Schwartz S, Daugherty C, Gallardo E, Hill C, et al. A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials. Pediatr Blood Cancer. 2023 Sep;70(9):e30506.; https://hdl.handle.net/11351/10260Test; 001017514700001

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Moreno L, Gros Subias L Vall d’Hebron Hospital Universitari, Barcelona, Spain. Teira P Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada. Croop JM Division of Hematology and Oncology, Riley Hospital for Children, Indianapolis, IN, United States. Gerber NU Department of Oncology, University Children’s Hospital, Zurich, Switzerland. André N SMARTC Unit Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix Marseille University, Marseille, France. Service d’Hématologie & Oncologie Pédiatrique, Timone Hospital, AP-HM, Marseille, France. Aerts I Institut Curie, Paris, France, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf; image/tiff

    العلاقة: Frontiers in Pediatrics;11; https://doi.org/10.3389/fped.2023.1183295Test; Moreno L, Teira P, Croop JM, Gerber NU, André N, Aerts I, et al. A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. Front Pediatr. 2023 May 24;11:1183295.; https://hdl.handle.net/11351/9743Test

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Servei d'Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Anales de Pediatría (English Edition);98(4); https://doi.org/10.1016/j.anpede.2022.03.009Test; Morell Daniel M, Pérez-Torres Lobato MR, Morey Olivé M, Gros Subias L. Malignant vaginal tumor: About a case. An Pediatr (Engl Ed). 2023 Apr;98(4):317-8.; https://hdl.handle.net/11351/9982Test; 000975778500001

  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية

    المساهمون: Amaro-Hosey K Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Danés I, Vendrell L, Vidal X, Agustí A Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Alonso L, Gros L Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Renedo B Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Cereza G Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Fundació Institut Català de Farmacologia. Vall Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Frontiers in Pharmacology;12; https://doi.org/10.3389/fphar.2021.670945Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F02018; Amaro-Hosey K, Danés I, Vendrell L, Alonso L, Renedo B, Gros L, et al. Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service. Front Pharmacol. 2021 May;12:670945.; https://hdl.handle.net/11351/6732Test; 000651753500001

  9. 9
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Escudero L, Arias A, Rubio-Perez C, Mayor R, Caratù G Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Llort A, Martínez-Sáez E, Vázquez-Méndez É, Hladun R, Gros L, Ramón Y Cajal S Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Diaz-Navarro A Dpto. de Bioquímica y Biología Molecular, IUOPA-Universidad de Oviedo, 33006 Oviedo, Spain. CIBERONC, Barcelona, Spain. Martínez-Ricarte F, Poca MA, Sahuquillo J, Gallego S Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Seoane J Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERONC, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Nature Communications;11; https://doi.org/10.1038/s41467-020-19175-0Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F01278; info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2013-45836-R; Escudero L, Llort A, Arias A, Diaz-Navarro A, Martínez-Ricarte F, Rubio-Perez C, et al. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. Nat Commun. 2020 Oct 27;11:5376.; https://hdl.handle.net/11351/6263Test; 000594622300001

  10. 10